Intensity Therapeutics resumes clinical trials, pursues partners for INT230-6
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
July 1, 2026 8:00 AM EDTLate-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer
Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published
Active strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profile
Strengthened balance sheet supporting disciplined clinical development strategy
SHELTON, Conn., July 1, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity"... More
